Intellia's single-dose CRISPR therapy cuts hereditary angioedema attacks in Phase 3 trial

Intellia Therapeutics reported that its gene-editing candidate lonvo-z produced a dramatic reduction in swelling attacks for patients with hereditary angioedema in a Phase 3 study.

The single-dose approach showed a clear benefit over baseline, suggesting the therapy could become a new treatment option for the rare disorder.

If the data are confirmed, the result would position lonvo-z as the second CRISPR-based drug to win regulatory approval, following Vertex's sickle-cell therapy.

The announcement came alongside news that Sun Pharmaceutical agreed to buy Organon for about $11.8 billion, highlighting continued M&A activity in the sector.